A new [(1R,2R)-1,2-diaminocyclohexane]platinum(II) complex: formation by nitrate-acetonitrile ligand exchange.

Institute of Chemical Technology, Technická 5, Prague 166 28, Czech Republic.
Acta Crystallographica Section C Crystal Structure Communications (Impact Factor: 0.78). 10/2010; 66(Pt 10):m273-5. DOI: 10.1107/S0108270110033135
Source: PubMed

ABSTRACT The title compound, cis-diacetonitrile[(1R,2R)-1,2-diaminocyclohexane-κ(2)N,N']platinum(II) dinitrate monohydrate, [Pt(C(2)H(3)N)(2)(C(6)H(14)N(2))](NO(3))(2)·H(2)O, is a molecular salt of the diaminocyclohexane-Pt complex cation. There are two formula units in the asymmetric unit. Apart from the two charge-balancing nitrate anions, one neutral molecule of water is present. The components interact via N-H...O and O-H...O hydrogen bonds, resulting in supramolecular chains. The title compound crystallizes only from acetonitrile with residual water, with the acetonitrile coordinating to the molecule of cis-[Pt(NO(3))(2)(DACH)] (DACH is 1,2-diaminocyclohexane) and the water forming a monohydrate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The impact of cisplatin on cancer chemotherapy cannot be denied. Over the past 20 years, much effort has been dedicated to discover new platinum-based anticancer agents that are superior to cisplatin or its analogue, carboplatin. Most structural modifications are based on changing one or both of the ligand types coordinated to platinum. Altering the leaving group can influence tissue and intracellular distribution of the drug, whereas the carrier ligand usually determines the structure of adducts formed with DNA. DNA-Pt adducts produced by cisplatin and many of its classical analogues are almost identical, and would explain their similar patterns of tumor sensitivity and susceptibility to resistance. Recently some highly innovative design strategies have emerged, aimed at overcoming platinum resistance and/or to introduce novel mechanisms of antitumor action. Platinum compounds bearing the 1,2-diaminocyclohexane carrier ligand; and those of multinuclear Pt complexes giving rise to radically different DNA-Pt adducts, have resulted in novel anticancer agents capable of circumventing cisplatin resistance. Other strategies have focused on integrating biologically active ligands with platinum moieties intended to selectively localizing the anticancer properties. With the rapid advance in molecular biology, combined with innovation, it is possible new Pt-based anticancer agents will materialize in the near future.
    Medicinal Research Reviews 10/2003; 23(5):633-55. · 9.58 Impact Factor
  • Journal of Pharmaceutical Sciences 04/1976; 65(3):315-28. · 3.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 25 years after the first approval of cisplatin in the clinic against a number of cancer diseases, cisplatin and related compounds continue to be among the most efficient anticancer drugs used so far. Efforts are focused to develop novel platinum- and non-platinum-based antitumor drugs to improve clinical effectiveness, to reduce general toxicity and to broaden the spectrum of activity. In the field of non-platinum compounds exhibiting anticancer properties, ruthenium complexes are very promising, showing activity on tumors which developed resistance to cisplatin or in which cisplatin is inactive. Furthermore, general toxicity was found to be very low. The first ruthenium compound NAMI-A entered phase I clinical trials in 1999 as an antimetastatic drug, whereas the ruthenium complex KP1019 will enter phase I clinical trials in 2003 as an anticancer drug which is among others very active against colon carcinomas and their metastases. Remarkable progress is also seen in developing tumor inhibiting gallium compounds. One of them, KP46, will also enter phase I clinical trials in 2003. This article reviews briefly the achievements in the field of anticancer metal complexes focusing the discussion onto the impact of the group of Bioinorganic Chemistry at the Department of Inorganic Chemistry at the University of Vienna. The development of pH sensitive platinum prodrugs, platinum-based drug targeting strategies with low-molecular-weight carriers, kinetically inert platinum(IV) complexes, as well as tumor inhibiting non-platinum anticancer drugs based on ruthenium and gallium is covered in the following sections.
    Current Pharmaceutical Design 02/2003; 9(25):2078-89. · 3.31 Impact Factor

Full-text (2 Sources)

Available from
Jun 6, 2014